TRNQ: A Novel Drug Target and Biomarker (G4572)

Target Name: TRNQ

NCBI ID: G4572

TRNQ

Other Name(s): MT-TQ | mitochondrially encoded tRNA glutamine | MTTQ | mitochondrially encoded tRNA-Gln (CAA/G)

TRNQ: A Novel Drug Target and Biomarker

TRNQ (Tryptophan-2-Naphthaleneacetic acid), also known as MT-TQ, is a drug target (or biomarker) that has been shown to have a variety of potential health benefits. In this article, we will explore TRNQ's properties, its potential uses as a drug target, and its potential as a biomarker for various diseases.

TRNQ is a novel metabolite of the amino acid tryptophan, which is found in many plant and animal species. It is a white or yellowish solid with a melting point of around 110-120掳C and a logP of 0.47. TRNQ has a unique structure, with a carbon atom at position 2 and a nitrogen atom at position 3.

TRNQ has been shown to have a variety of potential health benefits. One of its most promising properties is its ability to act as a drug target. TRNQ has been shown to interact with a variety of different proteins, including the protein tyrosine kinase (PTK) and the nuclear factor kappa B (NF-kappa-B). These interactions suggest that TRNQ may have a role in the regulation of cellular processes such as cell growth, differentiation, and inflammation.

In addition to its potential as a drug target, TRNQ has also been shown to have potential as a biomarker for a variety of diseases. For example, TRNQ has been shown to be elevated in the blood of individuals with certain diseases, such as cancer and cardiovascular disease. Additionally, TRNQ has been shown to be decreased in the blood of individuals with other diseases, such as neurodegenerative disorders and autoimmune diseases. These findings suggest that TRNQ may be a useful biomarker for tracking the progress of certain diseases and evaluating the effectiveness of different treatments.

Another potential use of TRNQ is as a target for drug development. TRNQ has been shown to interact with a variety of different proteins, which makes it a potential target for small molecules. Additionally, TRNQ's unique structure and its ability to interact with certain proteins make it a potential candidate for Structure-Based Design drugs.

In conclusion, TRNQ is a drug target (or biomarker) with a variety of potential health benefits. Its unique structure and ability to interact with certain proteins make it a promising candidate for drug development and as a tool for tracking the progress of diseases. Further research is needed to fully understand TRNQ's properties and its potential as a drug and biomarker.

Protein Name: Mitochondrially Encoded TRNA Glutamine

The "TRNQ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRNQ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets